春光药装
(838810)
| 流通市值：1.85亿 | | | 总市值：4.89亿 |
| 流通股本：2590.70万 | | | 总股本：6850.00万 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 10,747,829.83 | 165,071,927.79 | 146,079,179.3 | 108,328,729.67 |
| 营业收入 | 10,747,829.83 | 165,071,927.79 | 146,079,179.3 | 108,328,729.67 |
| 二、营业总成本 | 17,378,642.04 | 162,398,387.52 | 131,989,352.59 | 91,696,803.32 |
| 营业成本 | 7,289,132.28 | 111,842,655.21 | 95,581,635.95 | 67,966,250.77 |
| 税金及附加 | 278,614.53 | 1,796,186.72 | 1,420,865.7 | 1,174,132.92 |
| 销售费用 | 2,447,727.58 | 18,391,210.64 | 11,326,775.32 | 7,463,799.23 |
| 管理费用 | 5,319,489.96 | 20,034,930.99 | 15,003,444.97 | 9,946,249.57 |
| 研发费用 | 1,999,529.25 | 9,209,998.6 | 7,618,542.06 | 4,430,836.45 |
| 财务费用 | 44,148.44 | 1,123,405.36 | 1,038,088.59 | 715,534.38 |
| 其中:利息费用 | 665,132.85 | 2,590,344.84 | 1,918,881.82 | 1,209,340.88 |
| 其中:利息收入 | 635,235.77 | 1,531,680.5 | 874,069.67 | 503,324.78 |
| 加:投资收益 | 28,279.71 | 13,453.85 | 7,107.84 | 1,817.8 |
| 资产处置收益 | - | 51,216.02 | - | - |
| 资产减值损失(新) | 457,169.25 | 363,384.81 | -526,298.77 | -459,069.52 |
| 信用减值损失(新) | -417,522.35 | 1,656,885.06 | -3,199,026.52 | -3,808,704.62 |
| 其他收益 | 2,524,938.58 | 10,932,989 | 10,076,165.1 | 9,017,799.4 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -4,037,947.02 | 15,691,469.01 | 20,447,774.36 | 21,383,769.41 |
| 加:营业外收入 | 19,204.62 | 22,651.3 | 18,978.77 | 18,578.77 |
| 减:营业外支出 | - | 0.08 | 0.08 | - |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -4,018,742.4 | 15,714,120.23 | 20,466,753.05 | 21,402,348.18 |
| 减:所得税费用 | -516,928.81 | 1,550,828.32 | 1,789,873.46 | 2,768,866.01 |
| 六、净利润 | -3,501,813.59 | 14,163,291.91 | 18,676,879.59 | 18,633,482.17 |
| 持续经营净利润 | -3,501,813.59 | 14,163,291.91 | 18,676,879.59 | 18,633,482.17 |
| 归属于母公司股东的净利润 | -3,342,147.31 | 14,485,196.39 | 18,825,425.25 | 18,682,202.93 |
| 少数股东损益 | -159,666.28 | -321,904.48 | -148,545.66 | -48,720.76 |
| (一)基本每股收益 | -0.05 | 0.21 | 0.27 | 0.27 |
| (二)稀释每股收益 | -0.05 | 0.21 | 0.27 | 0.27 |
| 九、综合收益总额 | -3,501,813.59 | 14,163,291.91 | 18,676,879.59 | 18,633,482.17 |
| 归属于母公司股东的综合收益总额 | -3,342,147.31 | 14,485,196.39 | 18,825,425.25 | 18,682,202.93 |
| 归属于少数股东的综合收益总额 | -159,666.28 | -321,904.48 | -148,545.66 | -48,720.76 |
| 公告日期 | 2024-04-25 | 2024-04-25 | 2023-10-27 | 2023-08-21 |
| 审计意见(境内) | | 标准无保留意见 | | |